The advanced lung cancer inflammation index predicts outcomes of patients with non-small cell lung cancer following video-assisted thoracic surgery

Han, Zhaohui; Hu, Zhonghui; Zhao, Qingtao; Xue, Wenfei; Duan, Guochen

doi:10.1177/03000605211062442

Cited by 7 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous studies (9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20), our study found that NLR, PLR, LMR, SII, PIV, FAR, FPR, AGR, ALI, PNI, AAPR, CAR, RAR, APR, and FFA/Alb were all associated with OS in the univariate analysis. Even RAR, APR, and FFA/Alb, which were not evaluated in previous lung cancer association studies, were found to be independent predictors of prognosis in patients with NSCLC.…”

Section: Discussionsupporting

confidence: 92%

Fibrinogen-to-albumin ratio (FAR) is the best biomarker for the overall survival of patients with non-small-cell lung cancer

Ma,

Wang

2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThe inflammatory response and the nutritional status are associated with overall survival (OS) in patients with non-small cell lung cancer (NSCLC), but it is unclear which biomarkers are better suited to predict prognosis. This study sought to determine which of the commonly existing inflammatory and nutritional indicators best predicted the OS.MethodsThis study included 15 compound indicators based on inflammation or nutrition, with cutoff points obtained through the receiver operating characteristic (ROC) curve. Univariate and multivariate Cox proportional risk models were used to evaluate the relationship between these predictors and OS. Kaplan–Meier curves were used for survival analysis, and log-rank tests were used to compare differences between groups. The C-index was calculated to evaluate the predictive ability of the different indicators.ResultsThe study included 899 patients with NSCLC. In the univariate analysis, all 15 measures were significantly associated with the OS of patients (all p < 0.05). The results of the C-index analysis showed that the fibrinogen-to-albumin ratio (FAR), the systemic immune-inflammation index (SII), and the albumin-to-alkaline phosphatase ratio (AAPR) were the three indices with the best predictive performance. Among them, FAR (C-index = 0.639) had the best predictive power for OS in patients with NSCLC. In the different subgroups, FAR had the highest C-index in male, non-smoking, adenocarcinoma, and stage II patients. The C-index of the platelet-to-lymphocyte ratio (PLR) in female patients was the highest. SII was the highest in smokers, in those aged <65 and ≥65 years, and in stage III patients. The C-index of AAPR was the highest in non-adenocarcinomas. The C-index of the pan-immune-inflammation value (PIV) was the highest in stage I patients. In the multivariate Cox regression analysis, among FAR, SII, and AAPR, only FAR was an independent predictor of OS in patients with NSCLC. A high FAR was associated with a higher risk of death in patients with NSCLC (HR = 1.601, 95% CI = 1.028–2.495). In order to further evaluate the potential prognostic value of FAR, SII, and AAPR in patients with different stages, Cox regression analysis was performed for those with stage I–II and stage III NSCLC. The results showed that FAR was an independent prognostic factor for OS in patients with stage I–II NSCLC.ConclusionFor all patients with NSCLC, the prognostic power of FAR was superior to that of other inflammatory and nutritional indicators.

show abstract

Section: Discussionsupporting

confidence: 92%

Fibrinogen-to-albumin ratio (FAR) is the best biomarker for the overall survival of patients with non-small-cell lung cancer

Ma,

Wang

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

“…The indicators of systemic inflammatory response, including the neutrophil-to-lymphocyte ratio (NLR) (9), the platelet-to-lymphocyte ratio (PLR) (10), the lymphocyte-tomonocyte ratio (LMR) (11), the systemic immune-inflammation index (SII) (12), and the pan-immune-inflammation value (PIV) (13), are significant in determining the prognosis of patients with lung cancer. The fibrinogen-to-albumin ratio (FAR) (14), the fibrinogen-to-prealbumin ratio (FPR) (15), the albumin-toglobulin ratio (AGR) (16), the advanced lung cancer inflammation index (ALI) (17), the prognostic nutritional index (PNI) (18), the albumin-to-alkaline phosphatase ratio (AAPR) (19), and the C-reactive protein-to-albumin ratio (CAR) (20), as well as other inflammatory and nutritional complex indicators, are also biomarkers for predicting the prognosis of lung cancer. Furthermore, red cell distribution width-to-albumin ratio (RAR) (21), alkaline phosphatase-to-prealbumin ratio (APR) (22), free fatty acid (FFA) content (23), and other markers are significant predictors for cancer patients.…”

Section: Introductionmentioning

confidence: 99%

DataSheet_1.docx

View full text Add to dashboard Cite

“…[ 4 , 77 ], multiple studies subsequently confirmed that lower ALI tended to predict poor prognosis in patients with NSCLC [ 78 , 79 ]. Whether receiving targeted treatment [ 80 ], 1st line chemotherapy [ 81 ], radical surgery [ 82 , 83 ], or chemotherapy combined with targeted treatment [ 84 ], ALI shows prognostic value. Even in patients at the early stage of NSCLC, ALI also has a prognostic value [ 85 , 86 ].…”

Section: Albumin-related Inflammation Markers Based On Peripheral Blo...mentioning

confidence: 99%

Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence

et al. 2023

View full text Add to dashboard Cite

Inflammatory markers have a wide range of predictive values in the prognosis of non-small lung cancer (NSCLC). Poor nutritional status usually means a poor prognosis in patients with NSCLC, which is widely recognized by oncologists and nutritionists. Serum albumin has a certain value in evaluating the prognosis of patients. Several inflammatory albumin-related markers have been proposed, but they have not been widely used in predicting the prognosis of NSCLC in clinical practice. We aim to systematically review the published clinical evidence of albumin-related inflammatory markers in predicting the prognosis of NSCLC and to describe their progress and value. The results showed that the markers included in the review could be prognostic indicators in patients with NSCLC. However, we found that the cut-off value of albumin-related inflammatory markers with quantitative nature was very chaotic and needed to be defined by recognized standards. We summarized and compared the advantages and disadvantages of these markers, but a prospective cohort study with long-term follow-up after adjustment for important confounders is still necessary. Whether the results and conclusions could be directly applied in clinical practice needs to be identified and evaluated. There is an urgent need to classify and standardize the albumin-related inflammatory markers that play an important role in the prognosis of NSCLC, which is the key to ensuring the transformation from clinical study to clinical application.

show abstract

The advanced lung cancer inflammation index predicts outcomes of patients with non-small cell lung cancer following video-assisted thoracic surgery

Cited by 7 publications

References 42 publications

Fibrinogen-to-albumin ratio (FAR) is the best biomarker for the overall survival of patients with non-small-cell lung cancer

Fibrinogen-to-albumin ratio (FAR) is the best biomarker for the overall survival of patients with non-small-cell lung cancer

DataSheet_1.docx

Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence

Contact Info

Product

Resources

About